Currently, Neurocrine Biosciences, Inc [NBIX] is trading at $152.48, up 1.06%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBIX shares have gain 7.95% over the last week, with a monthly amount glided 6.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on October 21, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $175. Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $163. On July 10, 2025, Goldman initiated with a Buy rating and assigned a price target of $182 on the stock. Needham upgraded its rating to a Buy but stick to its price target of $138 on April 15, 2025. RBC Capital Mkts upgraded its rating to a Outperform but $137 remained the price target by the analyst firm on April 14, 2025. Deutsche Bank started tracking with a Hold rating for this stock on February 11, 2025, and assigned it a price target of $138.
This stock has fluctuated between a low of $84.23 and a high of $157.67 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $170.09 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $152.48 at the most recent close of the market. An investor can expect a potential return of 11.55% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Trailing Twelve Months sales for Neurocrine Biosciences, Inc [NASDAQ:NBIX] were 2.68B which represents 27.78% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.16 and Total Capital is 0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 150.95 points at the first support level, and at 149.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 153.90, and for the 2nd resistance point, it is at 155.32.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurocrine Biosciences, Inc [NASDAQ:NBIX] is 3.38. Also, the Quick Ratio is 3.27, while the Cash Ratio stands at 0.53. Considering the valuation of this stock, the price to sales ratio is 5.67, the price to book ratio is 5.06 and price to earnings (TTM) ratio is 36.41.
Transactions by insiders
Recent insider trading involved BENEVICH ERIC, Chief Commercial Officer, that happened on Nov 28 ’25 when 5970.0 shares were sold. Officer, ERIC BENEVICH completed a deal on Nov 28 ’25 to buy 5970.0 shares. Meanwhile, Director MORROW GEORGE J sold 15000.0 shares on Nov 25 ’25.
